SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
- PMID: 38822976
- PMCID: PMC11466990
- DOI: 10.1007/s12094-024-03502-8
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
Abstract
Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients' quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.
Keywords: Anorexia; Anorexia-cachexia syndrome; Cachexia; Cancer; Malnutrition; Sarcopenia.
© 2024. The Author(s).
Conflict of interest statement
ASR has participated in conferences for MSD, BMS, Novartis, Pierre Fabre, Regeneron, Merck Serono, Immunocore, Sanofi Aventis and Viatris; has participated in advisories for MSD, MS, Novartis, Immunocore, Regeneron; and he is on the steering committee of an IO biotech trial. LCG reports advisory board, speaker, personal fees from Roche; speaker, personal fees from Astra Zeneca, BMS, Merck Serono and MSD; advisory board from Eisai and speaker from Kyowa Kirin, Grunenthal and Pfizer. MMC, ABC, CBZ, YEA, MMT, KMM, MMS, MZP have nothing to disclose.
Figures
Similar articles
-
Cancer anorexia - cachexia syndrome.Acta Med Indones. 2012 Apr;44(2):154-62. Acta Med Indones. 2012. PMID: 22745148 Review.
-
Updates in Cancer-Related Symptom Management of Anorexia and Cachexia Syndrome.Semin Oncol Nurs. 2022 Feb;38(1):151254. doi: 10.1016/j.soncn.2022.151254. Semin Oncol Nurs. 2022. PMID: 35379449 Review.
-
Update on anorexia and cachexia.Hematol Oncol Clin North Am. 2002 Jun;16(3):589-617. doi: 10.1016/s0889-8588(02)00011-4. Hematol Oncol Clin North Am. 2002. PMID: 12170570 Review.
-
Assessment and nonpharmacological management for patients with cancer anorexia-cachexia syndrome: a best practice implementation project.JBI Evid Implement. 2022 Dec 1;20(4):334-343. doi: 10.1097/XEB.0000000000000315. JBI Evid Implement. 2022. PMID: 35275849
-
Clinical evaluation and optimal management of cancer cachexia.Crit Rev Oncol Hematol. 2013 Dec;88(3):625-36. doi: 10.1016/j.critrevonc.2013.07.015. Epub 2013 Aug 15. Crit Rev Oncol Hematol. 2013. PMID: 23953794 Review.
Cited by
-
Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.Int J Mol Sci. 2025 Apr 22;26(9):3952. doi: 10.3390/ijms26093952. Int J Mol Sci. 2025. PMID: 40362192 Free PMC article. Review.
References
-
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. 10.1016/S1470-2045(10)70218-7. - PubMed
-
- Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62. 10.1038/nrc3829. - PubMed
-
- Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–71. 10.1038/nrc927. - PubMed
-
- Dev R. Measuring cachexia-diagnostic criteria. Ann Palliat Med. 2019;8(1):24–32. 10.21037/apm.2018.08.07. - PubMed
-
- Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88(3):625–36. 10.1016/j.critrevonc.2013.07.015. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical